Estimates of global seasonal influenza-associated respiratory mortality: a modelling study AD Iuliano, KM Roguski, HH Chang, DJ Muscatello, R Palekar, S Tempia, ... The Lancet 391 (10127), 1285-1300, 2018 | 2368 | 2018 |
Economic burden of seasonal influenza in the United States WCWS Putri, DJ Muscatello, MS Stockwell, AT Newall Vaccine 36 (27), 3960-3966, 2018 | 463 | 2018 |
A systematic review of interventions in primary care to improve health literacy for chronic disease behavioral risk factors J Taggart, A Williams, S Dennis, A Newall, T Shortus, N Zwar, ... BMC family practice 13, 1-12, 2012 | 395 | 2012 |
Acute myocardial infarction and influenza: a meta-analysis of case–control studies M Barnes, AE Heywood, A Mahimbo, B Rahman, AT Newall, ... Heart 101 (21), 1738-1747, 2015 | 346 | 2015 |
A randomized clinical trial of three options for N95 respirators and medical masks in health workers CR MacIntyre, Q Wang, H Seale, P Yang, W Shi, Z Gao, B Rahman, ... American journal of respiratory and critical care medicine 187 (9), 960-966, 2013 | 255 | 2013 |
Cost-effectiveness analyses of human papillomavirus vaccination AT Newall, P Beutels, JG Wood, WJ Edmunds, CR MacIntyre The Lancet infectious diseases 7 (4), 289-296, 2007 | 177 | 2007 |
Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis MP Somes, RM Turner, LJ Dwyer, AT Newall Vaccine 36 (23), 3199-3207, 2018 | 172 | 2018 |
Which providers can bridge the health literacy gap in lifestyle risk factor modification education: a systematic review and narrative synthesis S Dennis, A Williams, J Taggart, A Newall, E Denney-Wilson, N Zwar, ... BMC Family Practice 13, 1-29, 2012 | 125 | 2012 |
Are current cost-effectiveness thresholds for low-and middle-income countries useful? Examples from the world of vaccines AT Newall, M Jit, R Hutubessy Pharmacoeconomics 32, 525-531, 2014 | 122 | 2014 |
Influenza-related hospitalisation and death in Australians aged 50 years and older AT Newall, JG Wood, CR MacIntyre Vaccine 26 (17), 2135-2141, 2008 | 117 | 2008 |
Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005 J Brotherton, H Wang, A Schaffer, H Quinn, R Menzies, B Hull, ... Communicable diseases intelligence quarterly report 31, S1-S152, 2007 | 116 | 2007 |
Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia AT Newall, JML Brotherton, HE Quinn, PB McIntyre, J Backhouse, ... Clinical infectious diseases 46 (11), 1647-1655, 2008 | 107 | 2008 |
Influenza-related disease: the cost to the Australian healthcare system AT Newall, PA Scuffham Vaccine 26 (52), 6818-6823, 2008 | 101 | 2008 |
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England D Cromer, AJ Van Hoek, AT Newall, AJ Pollard, M Jit The lancet Public health 2 (8), e367-e374, 2017 | 93 | 2017 |
The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis SS Liyanage, B Rahman, I Ridda, AT Newall, SN Tabrizi, SM Garland, ... PLoS One 8 (7), e69238, 2013 | 90 | 2013 |
Dealing with time in health economic evaluation: methodological issues and recommendations for practice JF O’Mahony, AT Newall, J van Rosmalen Pharmacoeconomics 33, 1255-1268, 2015 | 88 | 2015 |
The cost-effectiveness of rotavirus vaccination in Australia AT Newall, P Beutels, K Macartney, J Wood, CR MacIntyre Vaccine 25 (52), 8851-8860, 2007 | 88 | 2007 |
Global production capacity of seasonal and pandemic influenza vaccines in 2019 E Sparrow, JG Wood, C Chadwick, AT Newall, S Torvaldsen, A Moen, ... Vaccine 39 (3), 512-520, 2021 | 86 | 2021 |
Using economic evidence to set healthcare priorities in low‐income and lower‐middle‐income countries: a systematic review of methodological frameworks V Wiseman, C Mitton, MM Doyle‐Waters, T Drake, L Conteh, AT Newall, ... Health Economics 25, 140-161, 2016 | 82 | 2016 |
Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications E Sparrow, M Friede, M Sheikh, S Torvaldsen, AT Newall Vaccine 34 (45), 5442-5448, 2016 | 71 | 2016 |